Ono Licenses Biohaven's IgG Degraders: What the MoDE Platform Does
An $80 million upfront deal brings a new way of clearing autoantibodies to Asia. Here is how the liver-directed degraders work and what the early Graves' disease data do and do not show.
Anam
·
Oct 22, 2026
·
8 min read
